Medivir AB (STO:MVIR), a developer of drugs with a focus on cancer where the unmet medical needs are high, reported on Thursday the results of an analysis of data from the first six patients with advanced cancer in the liver treated with increasing MIV-818 doses, under the phase 1a study.
Reportedly, the primary objective of the study is to evaluate the tolerability, safety and pharmacokinetics of MIV-818.
According to Medivir, evaluated doses have been shown to be well-tolerated by patients. An effect signal, measured as DNA damage, has been observed in liver biopsies from tumour tissue in MIV-818 treated patients. In contrast to the tumour, normal liver tissue does not appear to have been affected by the treatment.
This tumour selective effect was observed at low measured levels of MIV-818 in plasma and is an early indication that MIV-818 works as expected, i.e. the substance has the intended liver-directed effect.
Based on the positive results from the first six patients, Medivir has decided to initiate the phase 1b part of the MIV-818 study.
MIV-818 is a pro-drug designed to selectively treat liver cancers and to minimise side effects. It has the potential to become the first liver-targeted, orally administered drug to benefit patients with HCC and other forms of liver cancer, Medivir said.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886